Skip to content

Induction to Labour With Double Cervical Ballon at Home Versus at Hospital

Induction to Labour With Double Cervical Ballon at Home Versus at Hospital to Improve the Vaginal Delivery Rate, Maternal Satisfaction and Reduce Costs: Multicentric Randomized Clinical Trial

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06053073
Acronym
INDOBAMHOS
Enrollment
834
Registered
2023-09-25
Start date
2023-03-27
Completion date
2026-03-31
Last updated
2023-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Dilatation, Induced; Birth, Live Birth

Brief summary

The goal of this clinical trial\] is to compare the outcomes between induction to labour at home versus hospitalized. The main questions it aims to answer are: * Can the induction to labour at home with cervical rippening ballon increase the vaginal delivery rate? * Will the induction to labour at home increase maternal satisfaction * Will the induction to labour at home improve medical circuits and coulb it be cost effective? Participants who meet inclusion criteria will undergo randomization so as to be asignated an induction to labour at home or in the hospital. Researchers will compare both labour induction groups to see if the induction to labour at home has better outcomes as described previously.

Detailed description

INDOBAMHOS is a multicentric randomized clinical trial which is based in the principle that cervical rippening with intracervical probes with ballons is as safe as pharmacological induction with PGE2 and it seems to be a suitable option to develop the cervical rippening process of the induction at home rather than in the hospital. The purpouse of the study is to demonstrate that the comfort of performing the cervical rippenning at home will benefit patients with an increase of the vaginal delivery rate and increases maternal satisfaction. And also will improve medical circuits and could be cost-effective when compared to hospitalized labour induction.

Interventions

DEVICECervical rippening at home

The experimental arm of the study will undergo cervical rippening at home between 6 and 8 hours and then will come back to the hospital to continue with the labor induction

DEVICECervical rippening in the hospital

The active comparator arm of the study will undergo cervical rippening in the hospital between 6 and 8 hours and then will remain there to continue with the labor induction

Sponsors

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Pregnant women with ages \>18 y.o * Being able to read and understand the informed consent * Accept to join the study when signing the informed consent * Singleton * Cephalic presentation * Weeks of gestation between equal or more than 37 and less than 42 * Low risk indication of labor induction: Cronologically prolonged gestation * Intermediate risk indication of labor induction: Macrosoma, Elevated maternal age, Intrahepatic Gestacional Colestasis, Gestational Diabetes Mellitus treated with diet, Gestational Diabetes Mellitus with insulin therapy and correct metabollic controls, Small for gestacional age fetus, Stable chronic hypertension, anterior caesarean section

Exclusion criteria

* Premature rupture of membranes (PROM) * Breech presentation * Unstable presentation * Polihydramnios * Severe congenital fetal afection * Fetal growth restriction * Suspected fetal well-being loss on CTG * Bishop score equal or higher than seven before insertion of the CRB * High cephalic presentation * Home further than 30min from Hospital * Preeclampsia * Diabetes Mellitus type 1 * Maternal Hypertension * Other maternal pathology with severe compromise * Vaginal delivery Exclusion: * Oclusive and non-occlusive placenta previa (marginal or low insertion) * Vasa previa * Transverse / Oblique situation * Cord prolapse * History of previous caesarean section with uterine incission in inverted T * History of uterine rupture * Two or more previous Caesarean section * Active genital herpetical infection

Design outcomes

Primary

MeasureTime frameDescription
Type of deliveryEnd of the deliveryVaginal birth, Cesarean section

Secondary

MeasureTime frameDescription
Edinburg questionnaire for postpartum depressionUp to two monthsScore obtained adding different items on the Scale
Impact of Event Scale-RevisedUp to two monthsScore obtained adding different items on the Scale
BreastfeedingUp to two monthsPresence of abscence
SF-12 questionnaireUp to two monthsScore obtained adding different items on the Scale
Diagnosis of depressionUp to two monthsPresence or Absence
Medical costsOne yearMeasured in euros
Indication of induction1 dayCathegorical variable, it will be studied the different reason that motivated the induction to delivery for each patient
ParityAt time of recruitment and end of delivery, about 1 or 2 daysNumber of pregnancies and deliveries of each patient
Weeks of gestationOnly at time of recruitment, 1 dayMeasured in number of weeks and days
Bishop scoreBefore inserting the rippening balloon and after removing it, about 6 hoursScore obtained when evaluating the different features of the uterine cervix by touch
Time of dilatationDuring labour and until delivery, between 1 and 3 daysHours
Time of cervical rippening balloonAt the insertion of the rippening balloon and after removing it, about 6 hoursHours
Partian emptying of the balloon due to painDuring cervical rippening, about 6 hoursMilliliters
Pharmacological analgesia during the cervical rippeningDuring cervical rippening, about 6 hoursNumber of drugs administered
Adverse outcomesDuring cervical rippening and labor, between 6 hours and 3 daysNumber of adverse outcomes
Artificial AmniorrhexisDuring cervical rippening and labor, between 6 hours and 3 daysPresence or absence
Oxytocin infusionDuring cervical rippening and labor, between 6 hours and 3 daysPresence or absence
Subsequent PGE2 useDuring cervical rippening and labor, between 6 hours and 3 daysPresence or absence
HyperstimulationDuring cervical rippening and labor, between 6 hours and 3 daysPresence or absence
Type of deliveryAt the moment of the delivery, between 1 day and 3Cathegorical variable, it will be studied the different type of delivery for each patient
Time to deliveryAt the moment of the delivery, between 1 day and 3Hours
Reason for instrumentationAt the moment of the delivery, between 1 day and 3Cathegorical variable, it will be studied the different reason of instrumentation
Reason for Cesarean sectionAt the moment of the delivery, between 1 day and 3Cathegorical variable, it will be studied the different reason of cesarean section
Epidural anesthesiaDuring cervical rippening and labor, between 6 hours and 3 daysPresence of absence
Days of postpartum hospitalizationFrom the delivery to discharge from hospital, between 1 and 7 daysDays
Fever during childbirthAt the moment of the delivery, between 1 day and 3Presence of absence
Perineal injuriesAt the moment of the delivery, between 1 day and 3Presence of absence
Postpartum haemorrageAt the moment of the delivery, between 1 day and 3Presence of absence
AnemiaAt the moment of the delivery, between 1 day and 3Presence of absence
Uterine ruptureAt the moment of the delivery, between 1 day and 3Presence of absence
Maternal ICU admissionAt the moment of the delivery, between 1 day and 3Presence of absence
SepsisAt the moment of the delivery, between 1 day and 3Presence of absence
Meconial amniotic fluidDuring cervical rippening and labor, between 6 hours and 3 daysPresence of absence
Arterial pHAt the moment of the delivery, between 1 day and 3pH value of neonatal umbilical artery
Venous pHAt the moment of the delivery, between 1 day and 3pH value of neonatal umbilical vein
APGAR scoreAt the moment of the delivery, between 1 day and 3Score obtained when evaluating neonatal apearance, heart rate, muscular tone, activity, breath, gestures
Neonatal Intensive Care Unit (NICU) admissionFrom the delivery to discharge from hospital, between 1 and 7 daysDays
Neonatal antibiotic administracionFrom the delivery to discharge from hospital, between 1 and 7 daysPresence of absence
Neonatal deathFrom the delivery to discharge from hospital, between 1 and 7 daysPresence of absence
Hypoxic-ischemic encephalopathyFrom the delivery to discharge from hospital, between 1 and 7 daysPresence of absence
Neonatal seizuresFrom the delivery to discharge from hospital, between 1 and 7 daysPresence of absence
Neonatal intubation or chest compressionsFrom the delivery to discharge from hospital, between 1 and 7 daysPresence of absence
Persistent pulmonary hypertension of the newbornFrom the delivery to discharge from hospital, between 1 and 7 daysPresence of absence
Pain/DiscomfortDuring insertion of the cervical balloon, between 1 and 3 minutesMeasure with analogue scale from 1 to 10
Labor Agentry ScaleUp to two monthsScore obtained adding different items on the Scale

Other

MeasureTime frameDescription
Language spoken at homeAt time of recruitment and end of delivery, about 1 or 2 daysCathegorical variable, it will be studied the different ethnicities of the patients
Socioeconomic dataAt time of recruitment and end of delivery, about 1 or 2 daysNumber of people in the home, type of dwelling, socio-professional category, level of education
Height and weightAt time of recruitment and end of delivery, about 1 or 2 daysMeasured in centimeters and kilograms, combined in Body Mass Index
EthnicityAt time of recruitment and end of delivery, about 1 or 2 daysCathegorical variable, it will be studied the different ethnicities of the patients
Maternal ageAt time of recruitment and end of delivery, about 1 or 2 daysYears

Countries

Spain

Contacts

Primary ContactMaria del Carmen Medina Mallén
mmedinam@santpau.cat0034646337446
Backup ContactIgnacio Montoro Pacha
imontorop@santpau.cat0034697596106

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026